Observational studyClinical drug investigation2020

Long-Term Safety and Effectiveness of the Xanthine Oxidoreductase Inhibitor, Topiroxostat in Japanese Hyperuricemic Patients with or Without Gout: A 54-week Open-label, Multicenter, Post-marketing Observational Study.

Tomohiko Ishikawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.